Anaveon

Anaveon is a clinical phase biopharmaceutical company that is developing antibodies and other protein-based biologics to modulate a patient’s immune system and address autoimmune diseases with high unmet need.

Anaveon is leveraging its extensive expertise in protein engineering and immune cell targeting to advance ANV200 towards the clinic. ANV200 is a PD-1 targeting T-cell depleting antibody with potential application in several autoimmune diseases, and the company is also building out an autoimmunity-focused pipeline behind it. In parallel, Anaveon is finalising execution of its Phase I/II clinical trial for ANV600 in oncology, with Syncona continuing to believe in the anticipated clinical safety and efficacy of this programme. Anaveon will continue to seek paths to progress the molecule towards pivotal trials, which will be subject to the company accessing further external capital.